Primary hyperoxaluria: Comprehensive mutation screening of the disease causing genes and spectrum of disease-associated pathogenic variants.
Aiysha AbidAli RazaAbdul Rafay KhanSadaf FirasatSaba ShahidSeema HashmiMirza Naqi ZafarSajid SultanShagufta KhaliqSyed Adib-Ul-Hasan RizviPublished in: Clinical genetics (2022)
The primary hyperoxalurias are rare disorders of glyoxylate metabolism. Accurate diagnosis is essential for therapeutic and management strategies. We conducted a molecular study on patients suffering from recurrent calcium-oxalate stones and nephrocalcinosis and screened primary hyperoxaluria causing genes in a large cohort of early-onset cases. Disease-associated pathogenic-variants were defined as missense, nonsense, frameshift-indels, and splice-site variants with a reported minor allele frequency <1% in controls. We found pathogenic-variants in 34% of the cases. Variants in the AGXT gene causing PH-I were identified in 81% of the mutation positive cases. PH-II-associated variants in the GRHPR gene are found in 15% of the pediatric PH-positive population. Only 3% of the PH-positive cases have pathogenic-variants in the HOGA1 gene, responsible to cause PH-III. A population-specific AGXT gene variant c.1049G>A; p.Gly350Asp accounts for 22% of the PH-I-positive patients. Pathogenicity of the identified variants was evaluated by in-silico tools and ACMG guidelines. We have devised a rapid and low-cost approach for the screening of PH by using targeted-NGS highlighting the importance of an accurate and cost-effective screening platform. This is the largest study in Pakistani pediatric patients from South-Asian region that also expands the mutation spectrum of the three known genes.
Keyphrases
- copy number
- genome wide
- early onset
- genome wide identification
- end stage renal disease
- dna methylation
- ejection fraction
- chronic kidney disease
- newly diagnosed
- low cost
- prognostic factors
- peritoneal dialysis
- escherichia coli
- mass spectrometry
- gene expression
- high throughput
- patient reported outcomes
- pseudomonas aeruginosa
- staphylococcus aureus
- single cell
- cancer therapy
- clinical practice
- cystic fibrosis
- single molecule